Why Is Soligenix (SNGX) Stock Up 296% Today?

Group 1 - Soligenix (NASDAQ:SNGX) stock has surged by 296% following positive data from its late-stage HyBryte treatment for early-stage cutaneous T-cell lymphoma (CTCL) [4][5] - In a 12-month study, six patients were enrolled, with four patients achieving a 50% improvement in their cumulative mCAILS score compared to baseline after at least 12 weeks of treatment [1][6] - Heavy trading activity was noted, with over 46 million SNGX shares changing hands, significantly above the daily average of approximately 222,000 shares [2] Group 2 - The company anticipates improved outcomes for patients with continued treatment and plans to embark on a confirmatory Phase 3 replication study later this year [5] - The interim data indicates that one patient has shown significant improvement over 18 weeks, contributing to the overall positive outlook for the therapy [1][6]